Skip to content
TrialScanner

NCT06444880

Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies

Phase 2RecruitingREGNCollaborator

Registry record

Lead sponsor
M.D. Anderson Cancer Center
Conditions
SMARCB1-Deficient Malignancies; Epithelioid Sarcoma; Renal Medullary Carcinoma
Primary completion
Jul 31, 2027Sponsor estimate
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Sponsor estimate: the sponsor registered this date in advance and can move it. A primary completion date is when the last participant is measured, not when results are announced.

Open NCT06444880 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

1 change recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT06444880: Phase II Trial of Ubamatamab... | TrialScanner